Harmony Biosciences Holdings Inc

For the period ended Dec 31, 2023. Filed Feb 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 22, 2024

HRMY$33.78+2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

	Page
Part I	3
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	3
ITEM 1. BUSINESS.	5
ITEM 1A. RISK FACTORS.	33
ITEM 1B. UNRESOLVED STAFF COMMENTS.	77
ITEM 1C. CYBERSECURITY	77
ITEM 2. PROPERTIES.	80
ITEM 3. LEGAL PROCEEDINGS.	80
ITEM 4. MINE SAFETY DISCLOSURES.	81
Part II	82
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.	82
ITEM 6: [RESERVED]	84
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	84
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	96
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.	97
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.	125
ITEM 9A. CONTROLS AND PROCEDURES.	126
ITEM 9B. OTHER INFORMATION.	128
ITEM 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	128
Part III	129
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.	129
ITEM 11. EXECUTIVE COMPENSATION.	129
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.	129
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.	129
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.	129
Part IV	130
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.	130
SIGNATURES	135

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents